Your browser doesn't support javascript.
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.
Küronya, Zsófia; Danyi, Tímea; Balatoni, Tímea; Liszkay, Gabriella; Tóth, Erika; Biró, Krisztina; Géczi, Lajos.
  • Küronya Z; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Ráth György str. 7-9, 1122, Budapest, Hungary. kuronyaz@gmail.com.
  • Danyi T; Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary.
  • Balatoni T; Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary.
  • Liszkay G; Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary.
  • Tóth E; Department of Pathology, National Institute of Oncology, Budapest, Hungary.
  • Biró K; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Ráth György str. 7-9, 1122, Budapest, Hungary.
  • Géczi L; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Ráth György str. 7-9, 1122, Budapest, Hungary.
J Med Case Rep ; 16(1): 396, 2022 Oct 31.
Article in English | MEDLINE | ID: covidwho-2267604
ABSTRACT

BACKGROUND:

The use of checkpoint inhibitors has become increasingly important in the treatment of different cancers, including advanced muscle-invasive urothelial cancer and even in basal cell carcinoma. We present the case of a patient with advanced basal cell carcinoma and metastatic muscle-invasive urothelial cancer, who was treated with the programmed death-ligand 1 inhibitor, atezolizumab for both cancers. CASE PRESENTATION A 72-year-old Caucasian female patient, with a history of smoking without any comorbidities developed periocular basal cell carcinoma, which was surgically removed but relapsed 4 years later. Surgical excision was carried out twice, but with positive margins, therefore definitive radiotherapy was given. Subsequently, the patient developed non-muscle-invasive papillary urothelial carcinoma, which was removed by transurethral resection. Follow-up was irregular owing to the patient's inadequate compliance, and within 2 years, the patient's cancer relapsed and histology confirmed muscle-invasive urothelial carcinoma. Definitive radiochemotherapy was not accepted by the patient. Meanwhile, the patient's basal cell carcinoma had also progressed, despite receiving vismodegib therapy. Therefore, the patient was administered epirubicin-cisplatin. Having reached the maximum cumulative dose of epirubicin, treatment with this chemotherapeutic agent could not be continued. The patient developed bladder cancer metastasis in her left suprainguinal lymph nodes. Owing to the presence of both types of tumors, programmed death-ligand 1 inhibitor atezolizumab treatment was chosen. In just over 1 year, the patient received 17 cycles of atezolizumab altogether, which was tolerated well without any adverse or side effects. Follow-up imaging scans indicated complete remission of the metastatic bladder cancer and stable disease of the basal cell carcinoma. The patient subsequently passed away in hospital due to a complication of COVID-19 infection.

CONCLUSIONS:

Our patient attained stable disease in advanced basal cell carcinoma and complete remission in metastatic muscle-invasive urothelial cancer after receiving programmed death-ligand 1 inhibitor, atezolizumab, therapy. To our knowledge, this is the first paper to report the use of programmed death-ligand 1 inhibitor, atezolizumab, as treatment for advanced basal cell carcinoma. This case may also be of interest for clinicians when treating patients with two synchronous cancers.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Skin Neoplasms / Urinary Bladder Neoplasms / Carcinoma, Basal Cell / Carcinoma, Transitional Cell / COVID-19 Type of study: Case report / Cohort study / Observational study / Prognostic study Limits: Aged / Female / Humans Language: English Journal: J Med Case Rep Year: 2022 Document Type: Article Affiliation country: S13256-022-03634-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Skin Neoplasms / Urinary Bladder Neoplasms / Carcinoma, Basal Cell / Carcinoma, Transitional Cell / COVID-19 Type of study: Case report / Cohort study / Observational study / Prognostic study Limits: Aged / Female / Humans Language: English Journal: J Med Case Rep Year: 2022 Document Type: Article Affiliation country: S13256-022-03634-x